Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease

REFERENCES

1. 1.↵
   1. Gabriel SE

   . Cardiovascular Morbidity and mortality in rheumatoid arthritis. Am J Med 2008;10 Suppl 1:S9–14.

   OpenUrl
2. 2.↵
   1. Solomon DH,
   2. Karlson EW,
   3. Rimm EB,
   4. Cannuscio CC,
   5. Mandl LA,
   6. Manson JE,
   7. et al.

   Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303–7.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Maradit-Kremers H,
   2. Crowson CS,
   3. Nicola PJ,
   4. Ballman KV,
   5. Roger VL,
   6. Jacobsen SJ,
   7. et al.

   Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: A population-based cohort study. Arthritis Rheum 2005;52:402–11.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. DeMaria AN

   . Relative risk of cardiovascular events in patients with rheumatoid arthritis. Am J Cardiol 2002;89:33D–8D.

   OpenUrlPubMed
5. 5.↵
   1. Avina-Zubieta JA,
   2. Thomas J,
   3. Sadatsafavi M,
   4. Lehman AJ,
   5. Lacaille D

   . Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012;71:1524–9.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Solomon DH,
   2. Avorn J,
   3. Katz JN,
   4. Weinblatt ME,
   5. Setoguchi S,
   6. Levin R,
   7. et al.

   Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:3790–8.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Dessein PH,
   2. Joffe BI,
   3. Veller MG,
   4. Stevens BA,
   5. Tobias M,
   6. Reddi K,
   7. et al.

   Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005;32:435–42.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Solomon DH,
   2. Kremer J,
   3. Curtis JR,
   4. Hochberg MC,
   5. Reed G,
   6. Tsao P,
   7. et al.

   Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Annals Rheum Dis 2010;69:1920–5.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Liao KP,
   2. Solomon DH

   . Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology 2013;52:45–52.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Roubille C,
    2. Richer V,
    3. Starnino T,
    4. McCourt C,
    5. McFarlane A,
    6. Fleming P,
    7. et al.

    The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015;74:480–9.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Avouac J,
    2. Allanore Y

    . Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opin Pharmacother 2008;9:1121–8.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Greenberg JD,
    2. Kremer JM,
    3. Curtis JR,
    4. Hochberg MC,
    5. Reed G,
    6. Tsao P,
    7. et al.

    Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:576–82.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Genovese MC,
    2. Becker J-C,
    3. Schiff M,
    4. Luggen M,
    5. Sherrer Y,
    6. Kremer J,
    7. et al.

    Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 2005;353:1114–23.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Kremer JM,
    2. Westhovens R,
    3. Leon M,
    4. Di Giorgio E,
    5. Alten R,
    6. Steinfeld S,
    7. et al.

    Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907–15.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Ursini F,
    2. Russo E,
    3. Letizia Hribal M,
    4. Mauro D,
    5. Savarino F,
    6. Bruno C,
    7. et al.

    Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study. Medicine 2015;94:e888.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Orban T,
    2. Bundy B,
    3. Becker DJ,
    4. DiMeglio LA,
    5. Gitelman SE,
    6. Goland R,
    7. et al;
    8. Type 1 Diabetes TrialNet Abatacept Study Group

    . Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 2014;37:1069–75.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Ursini F,
    2. Mauro D,
    3. Naty S,
    4. Gagliardi D,
    5. Grembiale RD

    . Improvement in insulin resistance after short-term treatment with abatacept: case report and short review. Clin Rheumatol 2012;31:1401–2.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Mathieu S,
    2. Couderc M,
    3. Glace B,
    4. Pereira B,
    5. Tournadre A,
    6. Dubost J-J,
    7. et al.

    Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis. Biologics 2013;7:259–64.

    OpenUrlPubMed
19. 19.↵
    1. Zhang J,
    2. Xie F,
    3. Yun H,
    4. Chen L,
    5. Muntner P,
    6. Levitan EB,
    7. et al.

    Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1813–8.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Kim SY,
    2. Servi A,
    3. Polinski JM,
    4. Mogun H,
    5. Weinblatt ME,
    6. Katz JN,
    7. et al.

    Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther 2011;13:R32.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Kiyota Y,
    2. Schneeweiss S,
    3. Glynn RJ,
    4. Cannuscio CC,
    5. Avorn J,
    6. Solomon DH

    . Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 2004;148:99–104.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Andrade SE,
    2. Harrold LR,
    3. Tjia J,
    4. Cutrona SL,
    5. Saczynski JS,
    6. Dodd KS,
    7. et al.

    a systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. Pharmacoepidemiol Drug Saf 2012;21 Suppl 1:100–28.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Kumamaru H,
    2. Judd SE,
    3. Curtis JR,
    4. Ramachandran R,
    5. Hardy NC,
    6. Rhodes JD,
    7. et al.

    Validity of Claims-Based Stroke Algorithms in Contemporary Medicare Data: REGARDS Study Linked with Medicare Claims. Circ Cardiovasc Qual Outcomes 2014;7:611–9.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Austin PC

    . Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput 2009;38:1228–34.

    OpenUrlCrossRef
25. 25.↵
    1. Kleinbaum DG,
    2. Klein M

    . Evaluating the proportional hazards assumption. In: Survival analysis: a self-learning text, third edition. New York: Springer New York; 2012:161–200.
26. 26.↵
    1. Klein JP,
    2. Goel PK

    1. Lee EW,
    2. Wei LJ,
    3. Amato DA,
    4. Leurgans S

    . Cox-type regression analysis for large numbers of small groups of correlated failure time observations. In: Klein JP, Goel PK, editors. Survival analysis: state of the art. Dordrecht: Springer Netherlands; 1992:237–47.
27. 27.↵
    1. Yoshida K,
    2. Solomon DH,
    3. Kim SC

    . Active-comparator design and new-user design in observational studies. Nature Rev Rheumatol 2015;11:437–41.

    OpenUrl
28. 28.↵
    1. Desai RJ,
    2. Solomon DH,
    3. Shadick N,
    4. Iannaccone C,
    5. Kim SC

    . Identification of smoking using Medicare data — a validation study of claims-based algorithms. Pharmacoepidemiol Drug Saf 2016;25:472–5.

    OpenUrl